Several variants are likely to be contributing to the nationwide trend, said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston.
“We’re seeing the start of an uptick of infections that is coincident with new variants that are developing: KP.2 and KP.3 and LB.1. It does appear that those variants do have an advantage over the prior ones,” he said. “It’s sort of the newest kid on the block,” Barouch said. “There’s not much known about it.” Read more…
https://cvvr.hms.harvard.edu/wp-content/uploads/2023/09/NBC.jpg10801080Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-06-26 10:08:042024-06-26 10:08:46The Covid Summer Wave is Here
“It looks like those additional mutations make it more immune evasive, so it’s not a surprise that it would then dominate,” said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. Read Full Article…
https://cvvr.hms.harvard.edu/wp-content/uploads/2023/09/NBC.jpg10801080Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-05-13 14:23:552024-05-13 14:23:55A new Covid variant has taken over, and experts predict a small summer wave
Whether shuttling between their lab’s two locations, in Boston’s Longwood Medical Area and Cambridgeport, or visiting the offices of Tome, their gene-editing startup, Gootenberg and Abudayyeh have become as well known in science circles for their friendship as their research and business ventures.
“Science is difficult, and it’s great to have someone to do it with,” said Gootenberg. “You got to work with people you enjoy hanging out with.” Read Full Article
https://cvvr.hms.harvard.edu/wp-content/uploads/2020/04/Boston-globe.jpg240240Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-02-15 13:51:412024-02-15 13:51:41A Jewish American and a Palestinian American are tackling science’s toughest challenges
“The reason why it hasn’t been eliminated is because there’s an animal reservoir. The bacteria can infect animals, and because we can’t treat all animals in the wild, it persists in nature and thus occasionally causes a limited number of human cases,” said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who is not involved in the Oregon case.
Barouch thinks it is “very unlikely” that the plague will spread beyond the person in Oregon. “As long as the person and their immediate contacts are treated — which did occur in this case — the chance it will spread any further is very, very low. So I think that people should not be worried, but if people want to reduce their risks, then they should avoid contact with rodents and fleas and sick animals,” he said. “It turns out cats can be infected quite easily because cats have a difficult time controlling the bacteria themselves,” Barouch said. “Dogs can be infected too, but cats can be infected even more easily. Squirrels, chipmunks, rodents are typically the animals that are infected in the wild.” Read Full Article.
https://cvvr.hms.harvard.edu/wp-content/uploads/2023/09/CNN.jpg10801080Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-02-14 09:14:332024-02-14 09:14:33Rare case of human plague identified in Oregon, likely spread by pet cat, health officials say
Dr. Dan Barouch, who runs the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, which helped develop a COVID vaccine for Johnson & Johnson, said that coronavirus vaccines were among the most lucrative pharmaceutical products ever. But, he said, “that will not likely be replicated unless we have another global pandemic, which, of course, we hope we won’t.” Read Full Article
https://cvvr.hms.harvard.edu/wp-content/uploads/2020/04/Boston-globe.jpg240240Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-01-29 16:16:312024-01-29 16:35:32Vaccines save lives and generate profits. Why is investment lagging?
“We are not going to be able to completely stop transmission, and we’re not going to be able to get rid of this virus in the human population,” said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. “Then, the decision of how to bring something into policy is really a summation of the medical risks as well as the risks to society as a whole.” Read Full Article
https://cvvr.hms.harvard.edu/wp-content/uploads/2023/09/CNN.jpg10801080Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-01-23 17:21:312024-01-23 17:27:23Some states are loosening their Covid isolation guidelines, shifting away from CDC recommendations
It also appears that HV.1 could also be slightly better at escaping prior immunity to COVID-19, but not enough to cause alarm, Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, told NBC News. Read Full Article…
https://cvvr.hms.harvard.edu/wp-content/uploads/2024/01/yahoo.png250250Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2024-01-04 09:40:582024-01-18 10:38:20COVID variant HV.1 is still spreading. These are its most common symptoms
“Whenever a new variant dominates, then by definition it has an advantage,” said Dr. Dan Barouch, the head of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. Read Full Article…
https://cvvr.hms.harvard.edu/wp-content/uploads/2023/09/NYT.jpg10801080Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2023-12-28 15:52:052023-12-28 15:52:20What to Know About the New Covid Variants
Vaccination rates have bottomed out just as some experts predict a COVID surge over the holidays. The JN.1 variant, which has triggered steep increases in waste water levels across Europe and is now becoming dominant in the United States, has developed mutations that make it more transmissible or better able to evade defenses, said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. Since more people will be infected, COVID-19 related deaths will inevitably rise. Yet the new boosters are a good match for the variant, making it especially important that those most at risk get the shot. Read Full Article…
https://cvvr.hms.harvard.edu/wp-content/uploads/2020/04/Boston-globe.jpg240240Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2023-12-22 10:43:532023-12-22 10:43:53With new COVID variant on horizon, low vaccination rates and stark disparities could make for a ‘miserable winter’
Dozens of mucosal COVID-19 vaccines are in development (see ‘High hopes’) and several have been approved in countries including China and India. But according to an 8 December report by the London-based data and analytics firm Airfinity, the efficacy of existing mucosal COVID-19 vaccines has been disappointing and the available data suggest that “they do not offer a meaningful increase in protection against infection”.
Source: Airfinity
However, the latest studies in monkeys and other laboratory animals offer hints on how these vaccines might be improved. A team led by Dan Barouch, a vaccine scientist at Beth Israel Deaconess Medical Center in Boston, Massachusetts, tried two approaches in monkeys that had previously received COVID-19 jabs: squirting a liquid vaccine into the animals’ noses, or applying it directly to their tracheae1.
Only the trachea-delivered vaccine substantially boosted mucosal immunity and protection against SARS-CoV-2 infection. “We think that the problem with intranasal delivery is that most of the vaccine is either swallowed or sneezed out,” Barouch says. The results were published in Nature on 14 December. Read Full Article…
https://cvvr.hms.harvard.edu/wp-content/uploads/2020/12/nature.jpg400400Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2023-12-22 10:41:452023-12-22 10:41:45Inhaled COVID vaccines stop infection in its tracks in monkey trials
Boston Globe
Nature
